Cargando…
Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trial
BACKGROUND: Lymphatic malformations (LMs) often pose treatment challenges due to a large size or a critical location that could lead to disfigurement, and there are no standardized treatment approaches for either refractory or unresectable cases. METHODS: We examined the genomic landscape of a patie...
Autores principales: | Shaheen, Montaser F, Tse, Julie Y, Sokol, Ethan S, Masterson, Margaret, Bansal, Pranshu, Rabinowitz, Ian, Tarleton, Christy A, Dobroff, Andrey S, Smith, Tracey L, Bocklage, Thèrése J, Mannakee, Brian K, Gutenkunst, Ryan N, Bischoff, Joyce, Ness, Scott A, Riedlinger, Gregory M, Groisberg, Roman, Pasqualini, Renata, Ganesan, Shridar, Arap, Wadih |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255965/ https://www.ncbi.nlm.nih.gov/pubmed/35787784 http://dx.doi.org/10.7554/eLife.74510 |
Ejemplares similares
-
Intracellular targeting of annexin A2 inhibits tumor cell adhesion, migration, and in vivo grafting
por: Staquicini, Daniela I., et al.
Publicado: (2017) -
Vascular Targeting: Recent Advances and Therapeutic Perspectives
por: Hajitou, Amin, et al.
Publicado: (2006) -
Selection on Network Dynamics Drives Differential Rates of Protein Domain Evolution
por: Mannakee, Brian K., et al.
Publicado: (2016) -
BATCAVE: calling somatic mutations with a tumor- and site-specific prior
por: Mannakee, Brian K, et al.
Publicado: (2020) -
Aminopeptidase N inhibitors and SARS
por: Kontoyiannis, Dimitrios P, et al.
Publicado: (2003)